Business Wire

EFPIA

13.5.2022 06:02:05 CEST | Business Wire | Press release

Share
Boosting Cardiovascular Health in Europe – Towards More Resilient and Equitable Healthcare

More than two years after the COVID-19 pandemic started, healthcare systems are taking stock of the lessons learnt to strengthen their response and improve the health outcomes of patients across disease areas. In this context, the European Federation of Pharmaceutical Industries and Associations (EFPIA) CVD Network commissioned a report in collaboration with PwC on “Boosting cardiovascular health in Europe: towards more resilient and equitable healthcare” , to assess the impact of COVID-19 on cardiovascular (CVD) care and to explore possible policy actions to strengthen the healthcare systems’ response to CVDs.

The report finds that:

  • Cardiovascular disease (CVD) is the major cause of mortality and morbidity across Europe, affecting almost 95 million patients and, notably causing 1.24 million acute coronary events each year.
  • CVD accounts for almost one-third of all premature deaths and is responsible for 23 % of all disability-adjusted life years (DALYs) measured across Europe, exceeding the burden caused by all other non-communicable diseases (NCDs), including cancer.
  • At the same time, many CVDs are preventable or, at least, manageable with appropriate interventions, often more so than other major NCDs. Overall, about 70% of the CVD burden is attributable to risk factors that can be controlled or modified, such as hypertension, high cholesterol or diabetes.
  • COVID-19 has made things worse. The pandemic has increased the risk of hospitalisation and death for people with CVD and put healthcare systems under strain, disrupting detection and care pathways and exposing existing disparities in CVD care.
  • Short-term shocks, similar to the pandemic, are likely to become more frequent, thus boosting healthcare demand, and stretching healthcare services even further.
  • Evolving disease patterns will force healthcare systems to reshape their care delivery models. With 130 million Europeans expected to be over the age of 65 by 2050, CVD-related healthcare demand is bound to grow and transform over the coming decades.

Following the findings, the report offers a series of concrete policy recommendations that aim to re-design CVD care and equip European healthcare systems with the necessary tools to cope with future crises:

  • Strengthen population screening
    • Broaden screening programmes for genetic and metabolic risk factors
    • Simplify access to screening, especially for vulnerable populations
  • Ensure treatment initiation, maintenance, and follow-up for at-risk patients
    • Re-design healthcare systems to reward outcomes
    • Strengthen digital health and information sharing to improve disease management
  • Foster data-driven decision making
    • Harness the potential of data-driven solutions to inform CVD policies and support clinical decision-making and value-based care delivery

“Cardiovascular diseases are Europe’s biggest health challenge. The time to act is now. Building on the available evidence, we need bold policy action for better population health in Europe ” commented Christian Thonke and Sean Lybrand, co-Chairs of the EFPIA CVD Network.

The Report calls on all CVD stakeholders to play their part in advancing CVD prevention, detection and care, by putting the spotlight on secondary prevention and encouraging a smarter use of digital technologies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 08:00:00 CEST | Press release

Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1Median time-to-next-treatment(TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1 Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous

Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 08:00:00 CEST | Press release

Megaport’s expansion to Portugal unlocks access to compute, network, and storage services for the local and global markets. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural

Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 18:09:00 CEST | Press release

Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,

Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press release

As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release

- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye